相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 US Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis
Matthew E. Falagas et al.
CLINICAL INFECTIOUS DISEASES (2013)
Saving Lives With Optimal Antimicrobial Chemotherapy
G. L. Drusano et al.
CLINICAL INFECTIOUS DISEASES (2013)
Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters
Nan-Yao Lee et al.
CLINICAL INFECTIOUS DISEASES (2013)
Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam
Michael N. Dudley et al.
CLINICAL INFECTIOUS DISEASES (2013)
Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
Teena Chopra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
β-Lactam/β-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
Jesus Rodriguez-Bano et al.
CLINICAL INFECTIOUS DISEASES (2012)
Can We Really Use ß-Lactam/ß-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ß-Lactamase-Producing Bacteria?
Federico Perez et al.
CLINICAL INFECTIOUS DISEASES (2012)
Transmission Dynamics of Extended-Spectrum β-lactamase-Producing Enterobacteriaceae in the Tertiary Care Hospital and the Household Setting
Markus Hilty et al.
CLINICAL INFECTIOUS DISEASES (2012)
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
J. W. Mouton et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli
Michael Hombach et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis
Konstantinos Z. Vardakas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum -lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis
Wouter C. Rottier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
Cheol-In Kang et al.
JOURNAL OF INFECTION (2012)
Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics
Alasdair MacGowan
CURRENT OPINION IN PHARMACOLOGY (2011)
Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective
Johan W. Mouton et al.
DRUG RESISTANCE UPDATES (2011)
Antimicrobial susceptibility of intra-abdominal Gram-negative bacilli from Europe: SMART Europe 2008
S. Hawser et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2011)
Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)
Daryl J. Hoban et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Community-Onset Bacteremia Due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli: Risk Factors and Prognosis
Jesus Rodriguez-Bano et al.
CLINICAL INFECTIOUS DISEASES (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Extended-Spectrum-beta-Lactamase, AmpC, and Carbapenemase Issues
Kenneth S. Thomson
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation Selecting the Best Antimicrobial Dose to Treat an Infection
John S. Bradley et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2010)
Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia
Anthony M. Nicasio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion
Leonardo Lorente et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
The changing epidemiology of resistance
Peter M. Hawkey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Cephalosporin MIC Distribution of Extended-Spectrum-β-Lactamase- and pAmpC-Producing Escherichia coli and Klebsiella Species
Peggy C. Kohner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli
Jesus Rodriguez-Bano et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations
A. MacGowan
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Breakpoints for intravenously used cephalosporins in Enterobacteriaceae - EUCAST and CLSI breakpoints
G. Kahlmeter
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Cefepime: a reappraisal in an era of increasing antimicrobial resistance
Andrea Endimiani et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2008)
Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation
Christopher R. Frei et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Extended-spectrum β-Lactamases: Implications for the Clinical Laboratory and Therapy
Sohei Harada et al.
KOREAN JOURNAL OF LABORATORY MEDICINE (2008)
Rapid emergence of blaCTX-M among Enterobacteriaceae in US medical centers:: Molecular evaluation from the MYSTIC program (2007)
Mariana Castanheira et al.
MICROBIAL DRUG RESISTANCE (2008)
Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms
Sunil V. Bhat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
Peter Ball
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia:: a systematic review and meta-analysis
Mitchell J. Schwaber et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
First report of the emergence of CTX-M-Type extended-spectrum β-lactamases (ES-BLs) as the predominant ESBL isolated in a US health care Systemdel
James S. Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment
C. Andrew DeRyke et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections
Su Young Lee et al.
JOURNAL OF INFECTION (2007)
CTX-M: changing the face of ESBLs in Europe
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Piperacillin-tazobactam for Pseudomonas aeruginosa infection:: Clinical implications of an extended-infusion dosing strategy
Thomas P. Lodise et al.
CLINICAL INFECTIOUS DISEASES (2007)
Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype
Helio S. Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Bacteremia due to extended-spectrum β-lactamase producing Escherichia coli in the CTX-M era:: A new clinical challenge
Jesus Rodriguez-Bano et al.
CLINICAL INFECTIOUS DISEASES (2006)
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
Juliana F. Roos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Kebsiella species
PJ Gavin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Interpretive breakpoints for fluconazole and Candida revisited:: a blueprint for the future of antifungal susceptibility testing
MA Pfaller et al.
CLINICAL MICROBIOLOGY REVIEWS (2006)
Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods:: report from the SENTRY Antimicrobial Surveillance Program
SM Bhavnani et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2006)
Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae:: Risk factors, molecular epidemiology, and clinical outcome
M Tumbarello et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004)
H Goossens et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations
D Andes et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Extended-spectrum β-lactamases:: a clinical update
DL Paterson et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Clinical implications of extended spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness
S Kotapati et al.
JOURNAL OF INFECTION (2005)
Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum β-lactamase-producing organisms
AM Reese et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Proteus mirabilis bloodstream infections:: Risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases
A Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Bactericidal activity of oral β-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum β-lactamases
B Bedenic et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation
TP Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Growing group of extended-spectrum beta-lactamases: The CTX-M enzymes
R Bonnet
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases:: Report from the ARREST program
PG Ambrose et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum β-lactamases
GS Babini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae:: Isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases
PE Coudron et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli
A Oliver et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Pharmacodynamics of cefepime in patients with Gram-negative infections
VH Tam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat
PA Bradford
CLINICAL MICROBIOLOGY REVIEWS (2001)
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases:: Implications for the clinical microbiology laboratory
DL Paterson et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region
PL Winokur et al.
CLINICAL INFECTIOUS DISEASES (2001)
分享论文
